Bicycle Therapeutics Q1 2026 net loss $60.8M, restructures, cuts 30% staff

BICYCLE THERAPEUTICS PLC

2026-Q1 EPS reported -$0.87 revenue$887,000

Net loss $60.8M ($0.87/sh) flat YoY; collaboration revenue dropped to $0.9M from $10.0M.
Cash $559.5M at March 31, 2026; expects runway into 2030 after cost cuts.
Workforce reduced ~30%; annual operating expenses expected to drop ~50%.
Duravelo-2 (zelenectide) converted to randomized Phase 2; Duravelo-3/4 trials discontinued.
Phase 2 trial of nuzefatide in pancreatic cancer started; first patient dosed April 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BICYCLE THERAPEUTICS PLC reported financial results for the fiscal quarter ended March 31, 2026.

Period: the fiscal quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On April 30, 2026, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended March 31, 2026 and other business highlights.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BICYCLE THERAPEUTICS PLC filing history →

Source: SEC EDGAR

accession 0001104659-26-052107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.